Dupilumab-associated ectropion and punctal stenosis treated with tacrolimus ointment (0.03%) in a 15-year-old girl

J AAPOS. 2022 Oct;26(5):275-278. doi: 10.1016/j.jaapos.2022.07.002. Epub 2022 Sep 13.

Abstract

A 15-year-old Asian girl with severe atopic dermatitis was referred for dupilumab-associated blepharoconjunctivitis. Medical history was significant for severe atopic dermatitis. She was started on prednisolone acetate 1% ophthalmic suspension three times daily, and dupilumab injections were withheld after the initial visit. The patient was noted to have right lower eyelid ectropion, cicatricial occlusion, and severe punctal stenosis 6 weeks later. She was started on 0.03% tacrolimus ointment to the eyelid margin. Resolution of ectropion and restoration of punctal patency with residual stenosis were observed 4 weeks later. This is the first reported adolescent case of dupilumab-associated ectropion and punctal stenosis successfully treated with topical tacrolimus ointment.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Constriction, Pathologic / complications
  • Dermatitis, Atopic* / complications
  • Ectropion* / chemically induced
  • Ectropion* / drug therapy
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Lacrimal Apparatus Diseases* / complications
  • Ointments
  • Tacrolimus / adverse effects
  • Treatment Outcome

Substances

  • Tacrolimus
  • dupilumab
  • Ointments
  • Immunosuppressive Agents